XBKK
BDMS
Market cap8.89bUSD
Nov 12, Last price
18.80THB
Name
Bangkok Dusit Medical Services PCL
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bangkok Dusit Medical Services Public Company Limited, along with its various subsidiaries, primarily operates a substantial network of healthcare facilities. The company owns and oversees six distinct hospital groups: the Bangkok Hospital Group, Samitivej Hospital Group, BNH Hospital, Phyathai Hospital Group, Paolo Hospital Group, and Royal Hospital Group. Its medical offerings are comprehensive, including holistic clinical wellness programs, laboratory testing, health insurance, telemedicine services for skin and aesthetics, genome sequencing, and air medical transportation. Beyond its core healthcare provision, the company diversifies its business interests. It manages hotels and restaurants, markets health and cosmetic products, and is involved in the manufacturing and distribution of pharmaceutical goods. The array of services provided also spans accounting, investment, information technology, training, insurance brokerage, facility and property management, as well as asset management. Additionally, Bangkok Dusit Medical Services engages in e-commerce and real estate ventures. The group's operational footprint includes a total of 47 hospitals spread across Thailand and Cambodia. Established in 1969, the company's headquarters are located in Bangkok, Thailand.
Key people
Kessara Wongsekate
Vice President, Company Secretary
Narumol Noi-am
Chief Financial Officer, Senior Executive Vice President, Executive Director · since 2020
Chairat Panthuraamphorn
Chief Operating Officer, Executive Director · since 2019
Poramaporn Prasarttong-Osoth
President, Executive Director · since 2024
Sripop Sarasas
Chief Administrative Officer, Executive Director · since 2018
Executive Director · since 2014
Att Thongtang
Executive Director · since 2023
Chuladej Yossundharakul
Executive Vice Chairman of the Board
Chokchai Jarusiripipat
Chief Medical Officer · since 2024
Thongchai Jira-alongkorn
Non-Executive Director · since 2023
Non-Executive Director · since 2018
Piyasakol Sakolsatayadorn
Independent Director · since 2025
Santasiri Sornmani
Non-Executive Independent Chairman of the Board · since 2021
Predee Daochai
Non-Executive Independent Director · since 2021
Veerathai Santiprabhob
Non-Executive Independent Director · since 2021
Chavalit Sethameteekul
Non-Executive Independent Director · since 2021
Subhak Siwaraksa
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2017
Valuation
Title THB in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||